TLR4 Agonist G100 clinical trials

Studies by the year they started

13 studies that test it; most in 2014 (3)

Who runs them

Industry 1 · Other 12

Access to Advanced Health Institute (AAHI) (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Mayo Clinic (1) · Fred Hutchinson Cancer Center (1) · University Hospital Tuebingen (1) · Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Oswaldo Cruz Foundation (1)

Often tested with

Tested in the same studies.

Aluminum Hydroxide (2) · LEISH-F3 (2) · Gla-af (2) · EM060G (1) · Nivolumab (1) · Ipilimumab (1)

Studies

Open first, then newest update. How each study uses TLR4 Agonist G100 is read from its arms, and is right about nine times in ten.

Testing it · 13

• Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy AdultsCompletedPhase 1Institut National de la Santé Et de la Recherche Médicale, FranceNCT02658253Written as GLA-SE
• Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and ChemotherapyWithdrawnPhase 1Gustave Roussy, Cancer Campus, Grand ParisNCT03982121Written as GLA-SE
• MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by SurgeryCompletedEarly Phase 1Mayo ClinicNCT02320305Written as TLR4 Agonist GLA-SE
• TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by SurgeryCompletedPhase 1Fred Hutchinson Cancer CenterNCT02180698Written as TLR4 Agonist GLA-SE
• Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously AdjuvantedCompletedPhase 1University Hospital TuebingenNCT02647489Written as GLA-SE
• A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell CarcinomaCompletedPhase 1Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT02035657Written as GLA-SE
• Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic RegionsCompletedPhase 2Oswaldo Cruz FoundationNCT03041766Written as GLA-SE solution
• Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult SubjectsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02508376Written as GLA-SE
• LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE VaccineCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT01751048Written as GLA-SE
• Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult VolunteersCompletedPhase 1Access to Advanced Health Institute (AAHI)NCT02071758Written as LEISH-F3 + GLA-SE
• The Effects of GLA (5 mcg) on Human VolunteersCompletedPhase 1Access to Advanced Health Institute (AAHI)NCT01864876Written as GLA-SE
• Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult VolunteersCompletedPhase 1Access to Advanced Health Institute (AAHI)NCT01484548Written as LEISH-F3 + GLA-SE
• The Effects of GLA on Human VolunteersCompletedPhase 1Rockefeller UniversityNCT01397604Written as GLA-SE